Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients – a multicenter retrospective observational study

Shimony, Shai; Yeshurun, Moshe; Wolach, Ofir; Ram, Ron; Rozovski, Uri; Shargian, Liat; Zukerman, Tsila; Amit, Odelia; Bar‐On, Yael; Krayem, Baher; Avni, Batia; Peretz, Galit; Raanani, Pia; Pasvolsky, Oren

doi:10.1080/10428194.2021.1913145

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, to reduce relapses in this high-risk population, various pre-, peri-, and post-transplantation strategies are emerging [ 40 ], and triplet treatment using target agents has recently been proposed [ 41 , 42 ]. Furthermore, several investigations of maintenance settings after allo-HCT have been conducted [ 43 , 44 , 45 , 46 ]; in particular, the results of the ongoing phase 3 VEN-AZA maintenance therapy study (VIALE-T, NCT04161885) are highly anticipated and should be noted.…”

Section: Discussionmentioning

confidence: 99%

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia

Bang

Park

Kwag

et al. 2023

Cancers

View full text Add to dashboard Cite

Recently, the combination of VEN-HMA has been shown to achieve durable responses in patients with both newly diagnosed (ND) and R/R-AML. We retrospectively evaluated the post-allo-HCT outcomes of 50 patients who received VEN-HMA therapy. In total, 10 were ND and 40 were R/R and, at the time of HCT, the median age was 53 years. In the ND- and R/R-AML groups, the percentage of patients who achieved CR/CRi or MLFS was 90% and 92.5%, respectively. In all, after a median follow-up of 13.7 months, the probabilities of overall survival (OS), relapse-free survival (RFS), cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM) at 1 year were 63.7%, 59.3%, 28.5%, and 12.2%, respectively. In addition, the cumulative incidences of grade II–IV acute graft-versus-host disease (GVHD) and moderate–severe chronic GVHD at 1 year were 28.4% and 37.4%, respectively. In multivariate analysis, the factors associated with a statistically significant impact on OS were VEN-HMA cycle (p = 0.021), ELN risk group (p = 0.041), and the response to VEN-HMA therapy before allo-HCT (p = 0.003). Although 80% of our patients had R/R-AML and 30% underwent a second allo-HCT, our data still suggest that allo-HCT following VEN-HMA therapy is a safe and effective treatment option.

show abstract

Section: Discussionmentioning

confidence: 99%

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia

Bang

Park

Kwag

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…A comparison between sorafenib and midostaurin was conducted in a multicenter retrospective cohort study by Shimony and colleagues [ 60 ]. Here, even though only 41 patients were included and most received pre-transplantation FLT3-TKI too, maintenance therapy with sorafenib was superior to midostaurin in terms of OS and RFS (HR for survival 0.25, CI 0.07–0.89).…”

Section: Maintenance Therapymentioning

confidence: 99%

FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation

Biavasco

Zeiser

2022

Int J Hematol

View full text Add to dashboard Cite

The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML) relies on the graft-versus-leukemia (GVL)-effect. Relapse after allo-HCT occurs in a considerable proportion of patients, and has a dismal prognosis with very limited curative potential, especially for patients with FLT-ITD-mutated AML. Since the first description of sorafenib for treatment of FLT3-ITD-mutated AML, several clinical trials have tried to determine the efficacy of FLT3 inhibitors for preventing and treating AML relapse after allo-HSCT, but many questions regarding differences among compounds and mechanisms of action remain unanswered. This review provides an overview on the established and evolving use of FLT3 inhibitors to prevent or treat relapse of AML in the context of allo-HCT, focusing on the recently discovered immunogenic potential of some FLT3 inhibitors and addressing the possible mechanisms of leukemia drug-escape.

show abstract

Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia

Yeh,

Pasvolsky,

Saliba

et al. 2024

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients – a multicenter retrospective observational study

Cited by 3 publications

References 18 publications

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia

FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation

Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia

Contact Info

Product

Resources

About